Abstract
In the last several years, bone tumor related microRNA research showed an explosive growth. MicroRNA was found to have a high or low expression level in bone tumor tissue and some microRNAs proved to be the biomarker for poor prognosis. The majority of research was focused on osteosarcoma and Ewing sarcoma. Many tumor associated molecules, including oncogenes and tumor suppressor genes, were found to be the direct targets for microRNA, and enhanced microRNA may play the regulatory role in tumor development. In the bone tumor cell lines, overexpression of microRNA could promote or inhibit the tumor growth, migration, invasion, and metastasis, especially for osteosarcoma and Ewing sarcoma. Many key molecules proved important for tumor genesis were found directly binding to the related microRNA, and whose expression level was down regulated. This may provide a novel therapeutic target for bone tumor. Large scale clinical samples detection and high through-put microarray assay have demonstrated microRNA might be applied to predict and diagnose the bone tumor. MicroRNA in serum was also proved significant as a biomarker for bone tumor.
Keywords: Bone tumor, Ewing sarcoma, microRNA, osteosarcoma.
Current Signal Transduction Therapy
Title:MicroRNA and Bone Tumor: To Up Date
Volume: 9 Issue: 3
Author(s): Huichao Wang, Ruiqiang Zhang, Yudong Jia, Xiaodong Zhang, Yingjie Zhu, Ying Zhang, Xiantao Chen, Xiaoqiang Zhang, Litao Cai, Hanzheng Zhao, Wuyin Li and Youwen Liu
Affiliation:
Keywords: Bone tumor, Ewing sarcoma, microRNA, osteosarcoma.
Abstract: In the last several years, bone tumor related microRNA research showed an explosive growth. MicroRNA was found to have a high or low expression level in bone tumor tissue and some microRNAs proved to be the biomarker for poor prognosis. The majority of research was focused on osteosarcoma and Ewing sarcoma. Many tumor associated molecules, including oncogenes and tumor suppressor genes, were found to be the direct targets for microRNA, and enhanced microRNA may play the regulatory role in tumor development. In the bone tumor cell lines, overexpression of microRNA could promote or inhibit the tumor growth, migration, invasion, and metastasis, especially for osteosarcoma and Ewing sarcoma. Many key molecules proved important for tumor genesis were found directly binding to the related microRNA, and whose expression level was down regulated. This may provide a novel therapeutic target for bone tumor. Large scale clinical samples detection and high through-put microarray assay have demonstrated microRNA might be applied to predict and diagnose the bone tumor. MicroRNA in serum was also proved significant as a biomarker for bone tumor.
Export Options
About this article
Cite this article as:
Wang Huichao, Zhang Ruiqiang, Jia Yudong, Zhang Xiaodong, Zhu Yingjie, Zhang Ying, Chen Xiantao, Zhang Xiaoqiang, Cai Litao, Zhao Hanzheng, Li Wuyin and Liu Youwen, MicroRNA and Bone Tumor: To Up Date, Current Signal Transduction Therapy 2014; 9 (3) . https://dx.doi.org/10.2174/1574362410666150116235118
DOI https://dx.doi.org/10.2174/1574362410666150116235118 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Apoptosis Pathways in Cancer Therapy
Current Cancer Drug Targets The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer
Current Pharmaceutical Design Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
Current Pharmaceutical Design Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene
Current Clinical Pharmacology The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Integrins Modulate Cellular Fibrogenesis at Multiple Levels: Regulation of TGF-β Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value
Current Drug Targets Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Screening GLP-1 Receptor Ligands from Natural Products in Herbs through High-Content Technique
Combinatorial Chemistry & High Throughput Screening P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry A Comprehensive Insight Towards Pharmaceutical Aspects of Graphene Nanosheets
Current Pharmaceutical Biotechnology Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Looking Beyond Inhibition of VEGF/mTOR: Emerging Targets for Renal Cell Carcinoma Drug Development
Current Clinical Pharmacology Role of Microtubules Network in CYP Genes Expression
Current Drug Metabolism Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry Biotechnological Applications of Bacterial Endophytes
Current Biotechnology